2021
Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data
Jackson CL, Colborn K, Gao D, Rao S, Slater HC, Parikh S, Foy BD, Kittelson J. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data. Clinical Trials 2021, 18: 582-593. PMID: 34218684, PMCID: PMC8478782, DOI: 10.1177/17407745211028581.Peer-Reviewed Original ResearchConceptsIvermectin mass drug administrationMass drug administrationCluster-randomized trialControl of malariaCluster-randomized trial designDrug AdministrationCrossover designMixed effects modelsTrial designStudy designCluster-level analysisSmall sample sizeCluster-level summariesCluster-level interventionsParallel trialRisk of harmPrimary analysisMalariaAdministrationMixed-effects modelsTrialsLevel interventionsSample sizeAdditional evaluationParallel design
2019
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. The Lancet 2019, 393: 1517-1526. PMID: 30878222, PMCID: PMC6459982, DOI: 10.1016/s0140-6736(18)32321-3.Peer-Reviewed Original ResearchConceptsMass drug administrationCluster-randomised trialIntervention groupMalaria episodesControl groupDrug AdministrationDetection cohortMass administrationIvermectin mass drug administrationUncomplicated malaria episodesClinical malaria episodesMalaria transmission seasonSingle oral dosesControl of malariaAdverse eventsCumulative incidencePrimary outcomeOral dosesEligible participantsAdverse reactionsFurther dosesTwo-armExclusion criteriaTransmission seasonTreatment phase